At-risk groups - DiabetesontheNet

This site is intended for healthcare professionals only

At-risk groups

Filter:

Mental health problems and diabetes

A look at the complex associations between diabetes and psychological well-being.

Reducing diabetes medication benefits older people

Polypharmacy increases complications and mortality in older people

Peripheral neuropathy reduces muscle strength in men with diabetes

Hypoglycaemia increases risk of adverse events in older patients with dementia

Deintensifying treatment benefits older patients with type 2 diabetes

Comorbid depression a growing concern in type 2 diabetes

Investigators examined a large general practice database to discover the patterns of comorbidities occurring in patients with type 2 diabetes over time. They quantified highly prevalent and well-recorded physical and mental health conditions, and then followed patients up at intervals over 9 years. They discovered that comorbidities are common in this population, with high between-patient variability in comorbidity patterns. They found that mental health is a growing concern and suggested that a population of people living with diabetes should have both their physical and mental health carefully addressed.

How to manage hyperglycaemia in people with severe mental illness

An overview of the information needed to screen, monitor and manage hyperglycaemia in those with severe mental illness.

Diabetes Distilled: Intensive intervention reduces stroke risk in diabetes with microalbuminuria

Steno-2 reveals that treating multiple risk factors reduces cerebrovascular events.

Intensive intervention reduces stroke risk in diabetes with microalbuminuria

Data from the Steno-2 Study were analysed to assess whether multiple risk factor intervention reduced the chance of stroke in individuals with type 2 diabetes and microalbuminuria. Participants were randomly allocated to intensified or conventional multifactorial intervention targeting classical cardiovascular disease risk factors. Post hoc analysis showed that the risk of stroke and number of recurrent cerebrovascular events were reduced with intensified multiple risk factor intervention in patients with type 2 diabetes and microalbuminuria.

Oral semaglutide significantly reduces cardiovascular events

An outcome study for oral semaglutide has evaluated the drug’s cardiovascular safety against placebo when added to standard care. Semaglutide is an injectable incretin that has recently become available; oral semaglutide has not yet been approved by the European Medicines Agency. Results showed no significant difference in three-point major adverse cardiac events, but there was a significant reduction in cardiovascular death and all-cause mortality with oral semaglutide.

No additional cardiovascular risk with linagliptin

The CARdiovascular Outcome Study of LINAgliptin versus glimepiride in patients with type 2 diabetes (CAROLINA) trial is the last planned cardiovascular outcome trial on a dipeptidyl peptidase 4 inhibitor. Researchers found that there were no substantial differences in cardiovascular events between linagliptin and glimepiride, although they found a significantly higher risk of hypoglycaemia and modest weight gain in the glimepiride group.

The Families with Diabetes National Network: Working with clinicians to improve care

Annie Astle highlights the role of the Families with Diabetes National Network, the research it carries out and the importance of collaboration.

Thinking big with Type 1 Kidz: Regional events, residential trips and charity status

Chloe Brown and Helen Mulhearn describe how Type 1 Kidz has adapted to challenges and worked creatively to ensure funding for the expanded project.

DigiBete: Recognition and development of the video platform and social enterprise

Frances Hanson and Maddie Julian report on recent DigiBete developments delivering improved clinical support and education in an online environment

Improvement in early glycaemia with carbohydrate counting from diagnosis in children with type 1 diabetes

Service changes to provide carb counting from diagnosis result in improved glycaemic control in the Bristol Royal Hospital for Children.

CGM during pregnancy a cost-effective CONCEPTT

Improvements in beta-cell function lost on treatment withdrawal

In this study, the effects of different pharmacological approaches to improving beta-cell function were compared in individuals with impaired glucose tolerance and in treatment-naive individuals with diabetes duration of less than a year. Participants were randomised to receive 12 months of metformin alone, insulin glargine followed by metformin, 12 months of liraglutide plus metformin or 12 months of placebo. Researchers found that pharmaceutical interventions improved beta-cell function during active treatment but failed to produce persistent benefits after treatment withdrawal in people with impaired glucose tolerance or recently-diagnosed type 2 diabetes.

Resources

For the latest news and articles

Sign up to all DiabetesontheNet journals

Follow us for all the latest news and updates in diabetes.

Resources

Journals

Useful information

© Copyright Omniamed Communications. All Rights Reserved
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom

;